FDA Tightens Indications for Using Long-Acting and Extended-Release Opioids to Treat Chronic Pain

• Autores: Bridget M. Kuehn
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 310, Nº. 15, 2013, págs. 1547-1548
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In an effort to help curb the ongoing epidemic of prescription opioid abuse and overdoses, the US Food and Drug Administration (FDA) is tightening the indications for long-acting and extended-release versions of these drugs and is requiring the drugs� manufacturers to conduct long-term postmarketing studies.

    �The FDA is concerned about inappropriate use of [opioid pain medications], which has reached epidemic proportions in the United States,� said FDA Commissioner Margaret A. Hamburg, MD, during a press briefing in September.